126 related articles for article (PubMed ID: 38659381)
1. Interferon-γ
Wu L; Deng H; Feng X; Xie D; Li Z; Chen J; Mo Z; Zhao Q; Hu Z; Yi S; Meng S; Wang J; Li X; Lin B; Gao Z
J Med Virol; 2024 May; 96(5):e29627. PubMed ID: 38659381
[TBL] [Abstract][Full Text] [Related]
2. Add-on pegylated interferon augments hepatitis B surface antigen clearance
Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
[TBL] [Abstract][Full Text] [Related]
3. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.
Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J
Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572
[TBL] [Abstract][Full Text] [Related]
5. Combination of pegylated interferon-alpha and nucleos(t)ide analogue treatment enhances the activity of natural killer cells in nucleos(t)ide analogue experienced chronic hepatitis B patients.
Pang X; Zhang L; Liu N; Liu B; Chen Z; Li H; Chen M; Peng M; Ren H; Hu P
Clin Exp Immunol; 2020 Oct; 202(1):80-92. PubMed ID: 32638357
[TBL] [Abstract][Full Text] [Related]
6. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
Wang Z; Li X; Shi C; Zhang M; Chen R; Wu W; Hou Q; Ke W; Fan T; Wen Z; Hao X; Qu N
Mol Med Rep; 2015 Jan; 11(1):427-33. PubMed ID: 25324041
[TBL] [Abstract][Full Text] [Related]
7. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon α enhances recovery of memory T cells in e antigen positive chronic hepatitis B patients.
Liu YZ; Hou FQ; Ding P; Ren YY; Li SH; Wang GQ
Virol J; 2012 Nov; 9():274. PubMed ID: 23158844
[TBL] [Abstract][Full Text] [Related]
9. [HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study].
Hu P; Shang J; Zhang WH; Gong GZ; Li YG; Chen XY; Jiang JN; Xie Q; Dou XG; Sun YT; Li YF; Liu YX; Liu GZ; Ma DW; Chi XL; Tang H; Li XO; Xie Y; Chen XP; Jiang JJ; Zha P; Hou JL; Gao ZL; Fan HM; Ding JG; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2018 Oct; 26(10):756-764. PubMed ID: 30481882
[No Abstract] [Full Text] [Related]
10. TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection.
Wang H; Luo H; Wan X; Fu X; Mao Q; Xiang X; Zhou Y; He W; Zhang J; Guo Y; Tan W; Deng G
J Hepatol; 2020 Jan; 72(1):45-56. PubMed ID: 31499130
[TBL] [Abstract][Full Text] [Related]
11. IP-10 Expression in Patients with Chronic HBV Infection and Its Ability to Predict the Decrease in HBsAg Levels after Treatment with Entecavir.
Zhao K; Yang T; Sun M; Zhang W; An Y; Chen G; Jin L; Shang Q; Song W
Mol Cells; 2017 Jun; 40(6):418-425. PubMed ID: 28614914
[TBL] [Abstract][Full Text] [Related]
12. Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN.
Islam M; Kumar K; Sevak JK; Jindal A; Vyas AK; Ramakrishna G; Kottilil S; Sharma MK; Sarin SK; Trehanpati N
Hepatol Commun; 2023 May; 7(5):. PubMed ID: 37102765
[TBL] [Abstract][Full Text] [Related]
13. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB.
Huang D; Wu D; Wang P; Wang Y; Yuan W; Hu D; Hu J; Wang Y; Tao R; Xiao F; Zhang X; Wang X; Han M; Luo X; Yan W; Ning Q
J Hepatol; 2022 Jul; 77(1):42-54. PubMed ID: 35149125
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus-specific T-cell responses during IFN administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue treatment.
Sprinzl MF; Russo C; Kittner J; Allgayer S; Grambihler A; Bartsch B; Weinmann A; Galle PR; Schuchmann M; Protzer U; Bauer T
J Viral Hepat; 2014; 21(9):633-41. PubMed ID: 24251783
[TBL] [Abstract][Full Text] [Related]
15. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
16. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
17. Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection.
Choi HSJ; Sonneveld MJ; Farag MS; Brouwer WP; Brakenhoff SM; Hirode G; Gehring AJ; de Man RA; Hansen BE; Janssen HLA
J Viral Hepat; 2021 Dec; 28(12):1729-1737. PubMed ID: 34514678
[TBL] [Abstract][Full Text] [Related]
18. CXCL13-mediated recruitment of intrahepatic CXCR5
Li Y; Tang L; Guo L; Chen C; Gu S; Zhou Y; Ye G; Li X; Wang W; Liao X; Wang Y; Peng X; Liu G; Zhang X; Sun J; Peng J; Hou J
J Hepatol; 2020 Mar; 72(3):420-430. PubMed ID: 31610223
[TBL] [Abstract][Full Text] [Related]
19. Changes of cytokine levels and T cell surface molecules in patients with chronic hepatitis B and the association with functional cure.
Xu Z; Lin JZ; Zeng YF; Yang XH; Wu ZB; Hu ZX; Zhao QY; Liu J; Gao ZL
J Med Virol; 2021 Aug; 93(8):4966-4974. PubMed ID: 33913556
[TBL] [Abstract][Full Text] [Related]
20. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
de Niet A; Jansen L; Stelma F; Willemse SB; Kuiken SD; Weijer S; van Nieuwkerk CMJ; Zaaijer HL; Molenkamp R; Takkenberg RB; Koot M; Verheij J; Beuers U; Reesink HW
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
